Articles related to RESEARCH & CLINICAL TRIALS

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.

The Trop-2-directed antibody-drug conjugate demonstrated a 2.3-month improvement in progression-free survival compared to standard chemotherapy options, offering a new treatment pathway for patients with limited options.

Multiple post-licensure studies have failed to demonstrate ticagrelor’s superiority over clopidogrel, prompting leading cardiologists to call for guideline reappraisal.

In a significant advancement for knee osteoarthritis treatment, LEVI-04 demonstrated pain reduction in more than 50% of treated patients, with effects lasting through 20 weeks of study.

Nearly half of clinical trial participants achieved such significant improvements that their OSA symptoms were effectively resolved, marking a significant advancement in treating this complex disorder.